NCT04016142 2026-03-18
ACCRAPAN
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
835 trialsNCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT02439034 2026-03-16
KETOCOL
Centre Oscar Lambret
Phase 2 Completed
NCT05231122 2026-03-16
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Roswell Park Cancer Institute
Phase 2 Recruiting
NCT05479045 2026-03-16
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients
Georgetown University
Phase 2 Not yet recruiting
NCT05521997 2026-03-13
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT05758688 2026-03-12
PROPS GYN
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05763199 2026-03-12
Standardized Extract of Cultured Lentinula Edodes Mycelia (AHCC®) in Ovarian Cancer Patients on Adjuvant Chemotherapy
University of California, Davis
Phase 2 Active not recruiting
NCT07050771 2026-03-12
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07467772 2026-03-12
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Not yet recruiting
NCT05952453 2026-03-11
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
University of Alabama at Birmingham
Phase 2 Recruiting
NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04341883 2026-03-10
Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer
Sun Yat-sen University
Phase 2 Completed
NCT04712851 2026-03-10
Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT05824481 2026-03-10
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT07454915 2026-03-09
PVX4 for the Treatment of Human Papilloma Virus (HPV)16+ Cervical Dysplasia
PapiVax Biotech, Inc.
Phase 2 Not yet recruiting
NCT00188539 2026-03-06
Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels
University Health Network, Toronto
Phase 2 Active not recruiting
NCT06820320 2026-03-06
Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Completed
NCT07454018 2026-03-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer
The First Affiliated Hospital of Soochow University
Phase 2 Not yet recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT06083844 2026-03-04
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06268665 2026-03-04
Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
University of California, Davis
Phase 2 Recruiting
NCT07447050 2026-03-03
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Phase 2 Recruiting
NCT06369155 2026-03-02
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07443475 2026-03-02
Electrochemotherapy for Recurrent Vulvar Cancer
Institute of Oncology Ljubljana
Phase 2 Recruiting
NCT04415944 2026-02-27
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT04742075 2026-02-27
DOVACC
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 2 Active not recruiting
NCT05063916 2026-02-27
Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06240598 2026-02-27
A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07033819 2026-02-27
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT07282834 2026-02-27
Charlie-2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Phase 2 Recruiting
NCT07435376 2026-02-27
INTLECTUAL
Seoul National University Bundang Hospital
Phase 2 Recruiting
NCT07439497 2026-02-27
DEHIM_CCRT
Samsung Medical Center
Phase 2 Recruiting
NCT07432594 2026-02-25
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT03617679 2026-02-23
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT06494150 2026-02-23
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
University of Oklahoma
Phase 2 Recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT07424664 2026-02-20
A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07107334 2026-02-18
A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia
University of Florida
Phase 2 Recruiting
NCT04251416 2026-02-17
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Yale University
Phase 2 Active not recruiting
NCT04780945 2026-02-17
FAB
Leiden University Medical Center
Phase 2 Terminated
NCT02397083 2026-02-13
LEVER
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05460000 2026-02-12
N-Plus
North Eastern German Society of Gynaecological Oncology
Phase 2 Recruiting
NCT07407452 2026-02-12
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Not yet recruiting
NCT07407647 2026-02-12
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03008408 2026-02-11
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04781088 2026-02-11
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05761951 2026-02-11
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting